3,800 Shares in Novo Nordisk A/S (NYSE:NVO) Purchased by Westside Investment Management Inc.

Westside Investment Management Inc. acquired a new position in Novo Nordisk A/S (NYSE:NVO) in the 2nd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor acquired 3,800 shares of the company’s stock, valued at approximately $193,000.

Other hedge funds also recently bought and sold shares of the company. Clearbridge Investments LLC raised its position in Novo Nordisk A/S by 42.3% in the first quarter. Clearbridge Investments LLC now owns 1,160,942 shares of the company’s stock worth $60,729,000 after acquiring an additional 344,989 shares in the last quarter. Janus Henderson Group PLC raised its position in Novo Nordisk A/S by 11.4% in the first quarter. Janus Henderson Group PLC now owns 247,811 shares of the company’s stock worth $12,963,000 after acquiring an additional 25,382 shares in the last quarter. Hartwell J M Limited Partnership raised its position in Novo Nordisk A/S by 7.2% in the first quarter. Hartwell J M Limited Partnership now owns 10,400 shares of the company’s stock worth $544,000 after acquiring an additional 700 shares in the last quarter. GYL Financial Synergies LLC bought a new stake in Novo Nordisk A/S in the first quarter worth about $1,090,000. Finally, Traynor Capital Management Inc. raised its position in Novo Nordisk A/S by 1.1% in the first quarter. Traynor Capital Management Inc. now owns 71,706 shares of the company’s stock worth $3,750,000 after acquiring an additional 810 shares in the last quarter. 7.12% of the stock is owned by institutional investors and hedge funds.

Several equities research analysts have commented on NVO shares. UBS Group reiterated a “buy” rating and issued a $355.00 price target on shares of Novo Nordisk A/S in a research report on Wednesday, June 19th. Pareto Securities upgraded Novo Nordisk A/S from a “hold” rating to a “buy” rating in a report on Monday. Zacks Investment Research upgraded Novo Nordisk A/S from a “sell” rating to a “hold” rating and set a $50.00 price objective on the stock in a report on Monday, July 15th. Credit Suisse Group upgraded Novo Nordisk A/S from a “neutral” rating to an “outperform” rating in a report on Monday, April 29th. Finally, Deutsche Bank downgraded Novo Nordisk A/S from a “buy” rating to a “hold” rating and set a $52.42 price objective on the stock. in a report on Thursday, June 20th. One investment analyst has rated the stock with a sell rating, ten have issued a hold rating and six have assigned a buy rating to the company’s stock. Novo Nordisk A/S currently has a consensus rating of “Hold” and an average target price of $111.58.

NYSE NVO traded up $0.78 on Tuesday, hitting $48.68. 28,427 shares of the company were exchanged, compared to its average volume of 1,774,372. The company’s 50 day moving average price is $49.69. The company has a quick ratio of 0.66, a current ratio of 0.96 and a debt-to-equity ratio of 0.07. The company has a market cap of $119.11 billion, a price-to-earnings ratio of 19.33, a P/E/G ratio of 2.23 and a beta of 0.60. Novo Nordisk A/S has a twelve month low of $41.23 and a twelve month high of $52.83.

Novo Nordisk A/S (NYSE:NVO) last posted its quarterly earnings data on Friday, May 3rd. The company reported $0.66 earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of $0.62 by $0.04. The firm had revenue of $4.46 billion for the quarter, compared to the consensus estimate of $4.35 billion. Novo Nordisk A/S had a return on equity of 78.28% and a net margin of 33.60%. Equities research analysts expect that Novo Nordisk A/S will post 2.43 earnings per share for the current fiscal year.

Novo Nordisk A/S Profile

Novo Nordisk A/S, a healthcare company, engages in the development, manufacture, and marketing of pharmaceutical products worldwide. It operates in two segments, Diabetes Care and Obesity, and Biopharmaceuticals. The Diabetes Care and Obesity segment provides products in the areas of insulins, GLP-1 and related delivery systems, oral anti-diabetic products, obesity, and other chronic diseases.

Featured Story: Why do corrections happen?

Want to see what other hedge funds are holding NVO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Novo Nordisk A/S (NYSE:NVO).

Institutional Ownership by Quarter for Novo Nordisk A/S (NYSE:NVO)

Receive News & Ratings for Novo Nordisk A/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Novo Nordisk A/S and related companies with MarketBeat.com's FREE daily email newsletter.